Abbott Laboratories (ABT): Today's Featured Drugs Loser
(
) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.5%. By the end of trading, Abbott Laboratories fell 62 cents (-1%) to $61.37 on average volume. Throughout the day, 5.9 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.4 million shares. The stock ranged in price between $61.04-$62.03 after having opened the day at $61.64 as compared to the previous trading day's close of $61.99. Other company's within the Drugs industry that declined today were:
(
), down 13.2%,
(
), down 8.7%,
(
), down 7.6%, and
Tekmira Pharmaceuticals Corporation
(
), down 7.5%.
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $97.25 billion and is part of the
sector. The company has a P/E ratio of 19.1, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 10.2% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.
TheStreet Ratings rates Abbott Laboratories as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
- You can view the full Abbott Ratings Report.
On the positive front,
(
), up 51.3%,
Accelr8 Technology Corporation
(
), up 17.3%,
(
), up 15.3%, and
(
), up 14.3%, were all gainers within the drugs industry with
(
) being today's featured drugs industry winner.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
